Chemotherapy in Ewing'S sarcoma: The Scandinavian Sarcoma Group experience

Acta Orthopaedica Scandinavica

Volumn 75, Issue sup311, 2004, Pages 87-91

  Smeland, S ^a   Wiebe, T ^b   Brosjo O ^c   Bohling T ^d   Alvegard T A ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; VINCRISTINE;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG MEGADOSE; DRUG RESPONSE; EWING SARCOMA; FOLLOW UP; HUMAN; LUNG METASTASIS; METASTASIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RISK FACTOR; SMALL CELL SARCOMA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL PROTOCOLS; HUMANS; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; REMISSION INDUCTION; SARCOMA, EWING'S; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342473262     PISSN: 00016470     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/00016470410001708370     Document Type: Article

References (19)

1. Alvegfird TA, Solheim O, Akerman M et al. Ewing's sar-coma. A preliminary report from the Scandinavian Sar-coma Group. Acta Oncol 1989; 28 (2): 59 – 64.
2. Bacci G, Picci P, Avella M et al. Neoadjuvant chemotherapy for localized Ewing's sarcoma of bone: experience at the Istituto Ortopedica Rizzoli. Cancer 1991; 4: 335 – 42.
3. Bacci G, Picci P, Ferrrari S et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding Ifosfamide and Etoposide to Vincristine, Actino-mycin, Cyclophosphamide and Doxorubicin in the main-tenance phase — results of two sequential studies. Cancer 1998; 6, 1174 – 83.
4. Bacci G, Ferrari S, Longhi A et al. Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemo-therapy. Oncol Rep, 2004; 11: 111 – 20.
5. Bacci G, Forth C, Longhi A et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapeies. 402 patietns treated at Rizzoli between 1972 and 1992. Eur J Cancer, 2004; 40: 73 – 83.
6. Burgert EOJ, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II J Clin Oncol 1990; 8: 1514 – 24.
7. Castello MA, Dominici C, Clerico A. A pilot study of 5-day continuous infusion of high-dose cisplatin and pulsed eto-poside in childhood solid tumors. Am J Pediatr Hematol Oncol 1988; 10: 103 – 8.
8. Cotterill SJ, Ahrens S, Paulussen M et al Prognostic factors in Ewings's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol, 2000; 18: 3108 – 14.
9. Dagher R, Long LM, Read EJ et al Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 158 – 64.
10. Elomaa I, Blomqvist CP, Saeter G et al. Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience. Acta orthop Scand (Suppl 285) 1999; 70 (285): 69 – 73.
11. Elomaa I, Blomqvist CP, Saeter G et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000; 36: 875 – 80.
12. Jiirgens H, Exner U, Gardner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer 1988; 61: 23 – 32.
13. Ladenstein R, Lasset C, Pinkerton R et al. Impact of mega-therapy in children with Mg-risk Ewing'stumours in com-plete remission. A report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697 – 705.
14. May WA, Gishizky ML, Lessnick SL. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLU for transformation. Proc Natl Acad Sci U S A. 1993; 90: 5752 – 6.
15. Meyers PA, Krailo MD, Ladanyi M et al. High-dose mel-phalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812 – 20.
16. Nilbert M, Saeter G, Elomaa I et al. Ewing's Sarcoma treat-ment in Scandinavia 1984-1990. Ten-year results of the Scnadinavian Sarcoma group protocol SSG IV Acta Oncol 1998; 37: 375 – 8.
17. Picci P, Rougraff BT, Bacci G et al. Prognostic significance of histopathologic response to chemotherapy in nonmeta-static Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763 – 9.
18. Picci P, Bohling T, Bacci G et al C Chemotherapy induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities J Chin Oncol 1997; 15: 1553 – 9.
19. Rosito P, Mancini AF, Abate ME et al. Italian cooperative study for treatment of localized Ewing's sarcoma of bone. Med Ped Oncol 1996; 27: 196.8: A1231.